NeuBase Therapeutics, Inc.
(NASDAQ : NBSE)

( )
NBSE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.93%54.040.9%$1956.39m
JNJJohnson & Johnson -0.82%165.210.7%$952.05m
ABBVAbbVie, Inc. -1.62%133.021.9%$896.21m
MRKMerck & Co., Inc. -0.69%80.730.7%$844.40m
BMYBristol-Myers Squibb Co. -0.17%64.611.0%$686.91m
LLYEli Lilly & Co. -0.76%243.201.1%$618.39m
AZNAstraZeneca Plc 1.16%60.171.0%$237.52m
NVSNovartis AG -0.75%88.180.2%$191.03m
GSKGlaxoSmithKline Plc -1.77%44.880.2%$165.07m
NVONovo Nordisk A/S -1.86%95.480.1%$149.54m
VTRSViatris, Inc. -0.54%14.640.0%$136.21m
RGENRepligen Corp. -0.59%188.466.7%$100.63m
ALLKAllakos, Inc. -3.37%7.180.0%$85.67m
IMMXImmix Biopharma, Inc. -4.24%5.420.0%$85.35m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.87%116.040.0%$75.90m

Company Profile

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.